Biocardia Stock Forward View - Triple Exponential Smoothing
| BCDA Stock | USD 1.23 0.03 2.38% |
Biocardia Stock outlook is based on your current time horizon. Investors can use this forecasting interface to forecast Biocardia stock prices and determine the direction of Biocardia's future trends based on various well-known forecasting models. We recommend always using this module together with an analysis of Biocardia's historical fundamentals, such as revenue growth or operating cash flow patterns.
At this time, the RSI of Biocardia's share price is approaching 42 suggesting that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Biocardia, making its price go up or down. Momentum 42
Sell Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.29) | EPS Estimate Current Year (1.25) | EPS Estimate Next Year (0.69) | Wall Street Target Price 15.5 | EPS Estimate Current Quarter (0.25) |
Using Biocardia hype-based prediction, you can estimate the value of Biocardia from the perspective of Biocardia response to recently generated media hype and the effects of current headlines on its competitors.
Biocardia Relative Strength Index
The Triple Exponential Smoothing forecasted value of Biocardia on the next trading day is expected to be 1.22 with a mean absolute deviation of 0.03 and the sum of the absolute errors of 2.05.Biocardia Hype to Price Pattern
Investor biases related to Biocardia's public news can be used to forecast risks associated with an investment in Biocardia. The trend in average sentiment can be used to explain how an investor holding Biocardia can time the market purely based on public headlines and social activities around Biocardia. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Biocardia's market sentiment to its price can help taders to make decisions based on the overall investors consensus about Biocardia.
The Triple Exponential Smoothing forecasted value of Biocardia on the next trading day is expected to be 1.22 with a mean absolute deviation of 0.03 and the sum of the absolute errors of 2.05. Biocardia after-hype prediction price | USD 1.27 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Biocardia | Build AI portfolio with Biocardia Stock |
Biocardia Additional Predictive Modules
Most predictive techniques to examine Biocardia price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Biocardia using various technical indicators. When you analyze Biocardia charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Biocardia Triple Exponential Smoothing Price Forecast For the 31st of January
Given 90 days horizon, the Triple Exponential Smoothing forecasted value of Biocardia on the next trading day is expected to be 1.22 with a mean absolute deviation of 0.03, mean absolute percentage error of 0, and the sum of the absolute errors of 2.05.Please note that although there have been many attempts to predict Biocardia Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Biocardia's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Biocardia Stock Forecast Pattern
| Backtest Biocardia | Biocardia Price Prediction | Buy or Sell Advice |
Biocardia Forecasted Value
In the context of forecasting Biocardia's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Biocardia's downside and upside margins for the forecasting period are 0.01 and 4.46, respectively. We have considered Biocardia's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Biocardia stock data series using in forecasting. Note that when a statistical model is used to represent Biocardia stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | -0.0042 |
| MAD | Mean absolute deviation | 0.0348 |
| MAPE | Mean absolute percentage error | 0.0261 |
| SAE | Sum of the absolute errors | 2.0538 |
Predictive Modules for Biocardia
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Biocardia. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biocardia's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Biocardia After-Hype Price Density Analysis
As far as predicting the price of Biocardia at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Biocardia or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Biocardia, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Biocardia Estimiated After-Hype Price Volatility
In the context of predicting Biocardia's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Biocardia's historical news coverage. Biocardia's after-hype downside and upside margins for the prediction period are 0.06 and 4.51, respectively. We have considered Biocardia's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Biocardia is moderately volatile at this time. Analysis and calculation of next after-hype price of Biocardia is based on 3 months time horizon.
Biocardia Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Biocardia is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biocardia backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Biocardia, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.11 | 3.24 | 0.01 | 0.02 | 8 Events / Month | 5 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
1.23 | 1.27 | 0.79 |
|
Biocardia Hype Timeline
Biocardia is currently traded for 1.23. The entity has historical hype elasticity of 0.01, and average elasticity to hype of competition of -0.02. Biocardia is forecasted to increase in value after the next headline, with the price projected to jump to 1.27 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is projected to be 0.79%, whereas the daily expected return is currently at -0.11%. The volatility of related hype on Biocardia is about 2189.19%, with the expected price after the next announcement by competition of 1.21. The company reported the previous year's revenue of 58 K. Net Loss for the year was (7.95 M) with loss before overhead, payroll, taxes, and interest of (5.25 M). Given the investment horizon of 90 days the next forecasted press release will be in about 8 days. Check out Historical Fundamental Analysis of Biocardia to cross-verify your projections.Biocardia Related Hype Analysis
Having access to credible news sources related to Biocardia's direct competition is more important than ever and may enhance your ability to predict Biocardia's future price movements. Getting to know how Biocardia's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Biocardia may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CELZ | Creative Medical Technology | (0.26) | 9 per month | 0.00 | (0.11) | 9.31 | (11.22) | 50.90 | |
| APRE | Aprea Therapeutics | 0.02 | 11 per month | 0.00 | (0.27) | 4.40 | (8.43) | 17.87 | |
| ACXP | Acurx Pharmaceuticals LLC | 0.08 | 5 per month | 0.00 | (0.18) | 10.84 | (9.84) | 49.19 | |
| KPRX | Kiora Pharmaceuticals | 0.07 | 8 per month | 0.00 | (0.05) | 5.32 | (5.58) | 16.69 | |
| HCWB | HCW Biologics | (0.13) | 9 per month | 0.00 | (0.23) | 13.02 | (11.97) | 41.72 | |
| ALZN | Alzamend Neuro | (0.08) | 8 per month | 0.00 | (0.03) | 6.12 | (5.33) | 21.59 | |
| ADIL | Adial Pharmaceuticals | 0.00 | 7 per month | 0.00 | (0.21) | 5.56 | (6.25) | 16.67 | |
| INAB | In8bio Inc | 0.26 | 8 per month | 5.05 | 0.01 | 14.29 | (9.18) | 37.96 | |
| PHIO | Phio Pharmaceuticals Corp | (0.07) | 8 per month | 0.00 | (0.26) | 4.88 | (9.27) | 19.15 | |
| APVO | Aptevo Therapeutics | (1.37) | 9 per month | 0.00 | (0.27) | 7.81 | (9.42) | 45.42 |
Other Forecasting Options for Biocardia
For every potential investor in Biocardia, whether a beginner or expert, Biocardia's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Biocardia Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Biocardia. Basic forecasting techniques help filter out the noise by identifying Biocardia's price trends.Biocardia Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biocardia stock to make a market-neutral strategy. Peer analysis of Biocardia could also be used in its relative valuation, which is a method of valuing Biocardia by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Biocardia Market Strength Events
Market strength indicators help investors to evaluate how Biocardia stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Biocardia shares will generate the highest return on investment. By undertsting and applying Biocardia stock market strength indicators, traders can identify Biocardia entry and exit signals to maximize returns.
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 1.23 | |||
| Day Typical Price | 1.23 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.03) | |||
| Relative Strength Index | 42.75 |
Biocardia Risk Indicators
The analysis of Biocardia's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Biocardia's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting biocardia stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 2.65 | |||
| Standard Deviation | 3.58 | |||
| Variance | 12.8 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Biocardia
The number of cover stories for Biocardia depends on current market conditions and Biocardia's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Biocardia is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Biocardia's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Biocardia Short Properties
Biocardia's future price predictability will typically decrease when Biocardia's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Biocardia often depends not only on the future outlook of the potential Biocardia's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Biocardia's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.7 M | |
| Cash And Short Term Investments | 2.4 M |
Check out Historical Fundamental Analysis of Biocardia to cross-verify your projections. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. Projected growth potential of Biocardia fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Biocardia assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Biocardia requires distinguishing between market price and book value, where the latter reflects Biocardia's accounting equity. The concept of intrinsic value—what Biocardia's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Biocardia's price substantially above or below its fundamental value.
It's important to distinguish between Biocardia's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biocardia should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biocardia's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.